Business
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.
About this update from Hansa Biopharma Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"As compared to prior year Q2 IDEFIRIX product sales increased 76%.","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":174,"olType":false},{"type":"text","content":"LUND, Sweden, July 17, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.","length":165,"tagName":"p"},{"type":"text","content":"Renée Aguiar-Lucander, CEO, Hansa Biopharma said, "In Q2 2025, the Company successfully secured additional financing and restructured its existing debt agreement with NovaQuest, ensuring the ability to report out data on two key Phase 3 programs in kidney transplantation and anti-GBM. With a cash runway now extending into Q2 2026, we can focus on near term catalysts, strategic pipeline decisions and driving the continued commercialization of IDEFIRIX in Europe."","length":476,"tagName":"p"},{"type":"text","content":"Financial Performance","length":21,"tagName":"p"},{"type":"text","content":"In Q2 2025, Hansa completed a successful capital raise with the support of new and existing shareholders. The funding will support two Phase 3 trial readouts in the second half of 2025 including the ConfIdeS US pivotal trial in kidney transplantation and GOOD-IDES-02 trial in anti-GBM.","length":286,"tagName":"p"},{"type":"text","content":"As part of a directed share issue, Hansa and NovaQuest entered into an amended debt agreement in which the Company offset US $14.9M of outstanding debt through the issue of new shares (equity). The remaining debt will be paid in fixed cash payments in June 2027, June 2028 and June 2029. In addition, a true-up payment of approximately US $14.9M is due on January 31, 2026, which may be settled in cash or equity at the Company's discretion. ","length":446,"tagName":"p"},{"type":"text","content":"IDEFIRIX Q2 product revenues increased by 76% as compared to the same period last year. In Q2 2025, the Company delivered 47.8 MSEK in IDEFIRIX sales reflecting an increase of 76% as compared to previous year (27.2 MSEK) for the same time period. For the 1H 2025, IDEFIRIX sales amounted to 113.5 MSEK r...